TY - JOUR
T1 - Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy
AU - Boddu, Prajwal
AU - Jain, Preetesh
AU - Borthakur, Gautam
AU - Verstovsek, Srdan
AU - Garcia-Manero, Guillermo
AU - Daver, Naval
AU - Kadia, Tapan
AU - Ravandi, Farhad
AU - Jabbour, Elias
AU - Cortes, Jorge
AU - Kantarjian, Hagop
N1 - Funding Information:
This study was supported by University of Texas MD Anderson Cancer Center Support Grant [P30 CA16672] and award P01 CA049639 from the National Cancer Institute (NCI). Jorge Cortes is the recipient of a grant from the NCI [P01 CA049639]. J.C. provided conception and design of the study, collection, analysis, and interpretation of data, provided patient data for study, writing and revising the manuscript, and final review and approval of the manuscript. P.B. and P.J. have contributed equally toward this manuscript and are first coauthors for this article; they contributed equally to data collection and analysis, and writing, reviewing, and approving the manuscript. H.K., G.B., G.G.M., S.V., T.K., N.J., and E.J. provided patient data for study, revision of the manuscript, and final review and approval of the manuscript. A.A. provided review of the manuscript.
Publisher Copyright:
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2019/11/10
Y1 - 2019/11/10
N2 - Considering the risk of arterio-thrombotic adverse events (AEs), ponatinib trials in previously untreated chronic myeloid leukemia chronic phase (CML-CP) were terminated. We conducted a retrospective CML-CP outcome study of patients who discontinued frontline-ponatinib. Among 51 patients who received frontline ponatinib, 38 discontinued because of FDA request and 13 due to AEs. At ponatinib discontinuation, all patients remained in CP with deepest response being CCyR, n = 7; PCyR, n = 4; MMR, n = 14; MR4.5, n = 26. Of the four patients in PCyR at ponatinib discontinuation, two improved response to CCyR on subsequent TKI. Of seven patients, in CCyR at discontinuation, five improved response to MMR or deeper, one was inevaluable, and another lost response due to treatment noncompliance. With a median follow-up of 39 months, 3-year EFS and OS were 92% and 96%, respectively, indicating favorable long-term outcomes. The cardiac/vascular system AEs with subsequent TKI occurred in patients with prior similar events on ponatinib. AEs occurred up to 9 months post-ponatinib.
AB - Considering the risk of arterio-thrombotic adverse events (AEs), ponatinib trials in previously untreated chronic myeloid leukemia chronic phase (CML-CP) were terminated. We conducted a retrospective CML-CP outcome study of patients who discontinued frontline-ponatinib. Among 51 patients who received frontline ponatinib, 38 discontinued because of FDA request and 13 due to AEs. At ponatinib discontinuation, all patients remained in CP with deepest response being CCyR, n = 7; PCyR, n = 4; MMR, n = 14; MR4.5, n = 26. Of the four patients in PCyR at ponatinib discontinuation, two improved response to CCyR on subsequent TKI. Of seven patients, in CCyR at discontinuation, five improved response to MMR or deeper, one was inevaluable, and another lost response due to treatment noncompliance. With a median follow-up of 39 months, 3-year EFS and OS were 92% and 96%, respectively, indicating favorable long-term outcomes. The cardiac/vascular system AEs with subsequent TKI occurred in patients with prior similar events on ponatinib. AEs occurred up to 9 months post-ponatinib.
KW - Ponatinib
KW - chronic myeloid leukemia
KW - chronic phase
KW - frontline
KW - outcomes
UR - http://www.scopus.com/inward/record.url?scp=85066911495&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066911495&partnerID=8YFLogxK
U2 - 10.1080/10428194.2019.1617862
DO - 10.1080/10428194.2019.1617862
M3 - Article
C2 - 31125272
AN - SCOPUS:85066911495
SN - 1042-8194
VL - 60
SP - 3172
EP - 3180
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 13
ER -